Darbepoetin- does not affect survival in SCLC

  • Published on
    09-Dec-2016

  • View
    212

  • Download
    0

Transcript

  • Inpharma 1585 - 28 Apr 2007

    Darbepoetin- does not affect overall survival inpatients with extensive-stage small-cell lung cancer(SCLC), according to the results of a multicentre,phase III study. Data were evaluated from 600 suchtreatment-naive patients who were randomised 1:1 toreceive darbepoetin- 300g or placebo, every weekfor 4 weeks, followed by three-weekly dosing for21 weeks, in addition to platinum-containingchemotherapy. There was no significant difference inoverall survival with darbepoetin- and placebo;progression-free survival was also similar fordarbepoetin- recipients and placebo recipients.However, darbepoetin- was associated with asignificant change from baseline in haemoglobinconcentration, compared with placebo. Furthermore,darbepoetin- recipients had a significantly reducedrisk of blood transfusions, compared with placeborecipients.See also page 20 of this issue; 801069309 andInpharma 1579 p22; 801013918Amgen. Aranesp(Rm) "145 Study Shows No Difference in Survival inPatients with Small-Cell Lung Cancer. Media Release : 20 Apr 2007.Available from: URL: http://www.amgen.com 809074659

    1

    Inpharma 28 Apr 2007 No. 15851173-8324/10/1585-0001/$14.95 Adis 2010 Springer International Publishing AG. All rights reserved

Recommended

View more >